The current stock price of SLGC is 2.1 USD. In the past month the price decreased by -22.51%. In the past year, price decreased by -19.54%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 25.62 | 215.59B | ||
| DHR | DANAHER CORP | 29.89 | 162.76B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 181.32 | 55.10B | ||
| A | AGILENT TECHNOLOGIES INC | 25.71 | 40.67B | ||
| IQV | IQVIA HOLDINGS INC | 19.17 | 37.96B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 33.6 | 28.72B | ||
| WAT | WATERS CORP | 31.17 | 23.56B | ||
| ILMN | ILLUMINA INC | 30.94 | 20.61B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 37.76 | 19.21B | ||
| MEDP | MEDPACE HOLDINGS INC | 39.21 | 15.80B | ||
| TEM | TEMPUS AI INC | N/A | 13.36B | ||
| RVTY | REVVITY INC | 21.61 | 11.74B |
SomaLogic, Inc. is a commercial-stage proteomics company, which built an integrated proteomics platform for robust, high throughput proteomics analysis, research and clinical applications. The company is headquartered in Boulder, Colorado and currently employs 451 full-time employees. The company went IPO on 2021-02-23. The firm has built an integrated proteomics platform, which offers throughput proteomics analysis with broad proteome coverage. The company develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein. The company offers SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. Its products include SomaScan Assay, SomaScan Certified Sites, SomaSignal Tests and SOMAmer Reagents. SomaScan Assay is utilized for Research Use Only (RUO) applications. Its SomaScan Assay measures approximately 7,000 protein target measurements in a single sample. Its SOMAmer reagents are proprietary modified aptamers, which are short, synthetic single-stranded DNA (ssDNA) sequences developed to bind specific protein targets with high affinity and specificity across the proteome.
SOMALOGIC INC
C/O Somalogic, Inc., 2945 Wilderness Place
Boulder COLORADO US
Employees: 451
Phone: 13036259000
SomaLogic, Inc. is a commercial-stage proteomics company, which built an integrated proteomics platform for robust, high throughput proteomics analysis, research and clinical applications. The company is headquartered in Boulder, Colorado and currently employs 451 full-time employees. The company went IPO on 2021-02-23. The firm has built an integrated proteomics platform, which offers throughput proteomics analysis with broad proteome coverage. The company develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein. The company offers SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. Its products include SomaScan Assay, SomaScan Certified Sites, SomaSignal Tests and SOMAmer Reagents. SomaScan Assay is utilized for Research Use Only (RUO) applications. Its SomaScan Assay measures approximately 7,000 protein target measurements in a single sample. Its SOMAmer reagents are proprietary modified aptamers, which are short, synthetic single-stranded DNA (ssDNA) sequences developed to bind specific protein targets with high affinity and specificity across the proteome.
The current stock price of SLGC is 2.1 USD. The price decreased by -4.55% in the last trading session.
SLGC does not pay a dividend.
SLGC has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
SLGC stock is listed on the Nasdaq exchange.
SOMALOGIC INC (SLGC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.69).
SOMALOGIC INC (SLGC) has a market capitalization of 396.23M USD. This makes SLGC a Small Cap stock.
ChartMill assigns a technical rating of 1 / 10 to SLGC. When comparing the yearly performance of all stocks, SLGC is a bad performer in the overall market: 78% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to SLGC. SLGC has a great financial health rating, but its profitability evaluates not so good.
Over the last trailing twelve months SLGC reported a non-GAAP Earnings per Share(EPS) of -0.69. The EPS decreased by -50% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -23.08% | ||
| ROE | -26.25% | ||
| Debt/Equity | 0 |
10 analysts have analysed SLGC and the average price target is 4.01 USD. This implies a price increase of 91.05% is expected in the next year compared to the current price of 2.1.
For the next year, analysts expect an EPS growth of -2.43% and a revenue growth -12.14% for SLGC